Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma
BRIEF-Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma Oct 27 (Reuters) - Pfizer Inc. PFE.N:
PFIZER’S ELREXFIO OUTPERFORMS STANDARD REGIMENS AND MEETS PRIMARY ENDPOINT IN PHASE 3 STUDY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
PFIZER - ELREXFIO SHOWS STATISTICALLY SIGNIFICANT BENEFIT WITH MEDIAN PFS NOT YET REACHED IN RRMM
PFIZER - ELREXFIO MEETS PRIMARY ENDPOINT IN PHASE 3 MAGNETISMM-32 STUDY FOR RRMM
PFIZER - OVER 75% OF ELREXFIO PATIENTS PROGRESSION-FREE; ESTIMATED 68% PFS AT 18 MONTHS
PFIZER - GRADE 3+ INFECTIONS IN 27.5% ELREXFIO PATIENTS VERSUS 18.1% INVESTIGATOR'S CHOICE; GRADE 5: 0.8% VERSUS 1.6%
PFIZER - PLANS GLOBAL HEALTH AUTHORITY SUBMISSIONS AND FUTURE PUBLICATION OF MAGNETISMM-32 RESULTS
PFIZER: SAFETY PROFILE OF ELREXFIO IN MAGNETISMM-32 WAS CONSISTENT WITH ITS KNOWN PROFILE
Source text: ID:nBw9NM9nSa
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma